A trial of AstraZeneca’s key immunotherapy drug, Durvalumab showed it reduced disease progression in lung cancer patients. As a result this sent the company’s shares higher and gave it a lead over rivals as it seeks to transform its oncology business. The trial results are an unexpectedly early boost for the product, known commercially as Imfinzi. “These are highly encouraging results for patients with locally-advanced lung cancer for whom surgery is not an option,” Sean Bohen, Executive Vice President, Global Medicines Development at AstraZeneca, said in a statement.